Nature is just another political rag.
3 Likes
The FDA will have something to say about that, since they’re now intent on inspecting every package coming from overseas.
2 Likes
Nature Climate Change. I’m not an expert in journals, but they also have this one in there:
https://www.nature.com/articles/s41558-025-02407-w
Which tries to prove you age faster when it gets hot out from heatwaves. It makes me wonder if they’ve heard of sauna, or heat shock proteins. Also my understanding is that we’ve been on the planet for 250000 years in about this same form and have been through it and adapted to it, whether in the arctic or around the equator. Not to cause trouble, but my understanding based on what phd’s and papers I’ve read is that much of the small increase in heat worldwide is from higher nightime temps from extra moisture in the air from having more foliage, so higher dew point. It works even more convincingly at the poles in the winter, moderating what used to be more extremely low temps.
If what they’re doing is science, then I’ve lost faith.
2 Likes
I’m really not interested in engaging any kind of discussion on climate change denialism, much less in a thread that is supposed to be about GLP-1 experiences.
6 Likes
It’s Nature Climate Change, not Nature. (still a good journal)
2 Likes
Good table showing the GLP-1RAs pipeline by indication: https://www.primetherapeutics.com/documents/d/primetherapeutics/glp-1-pipeline-update-table-august-2025
I’m surprised that no one seems to be working on GLP-1RAs for conditions in non-diabetic and non-overweight people. SGLT2i were approved in HF and CKD. How come GLP-1RAs aren’t approved (or even explored?) in HF or CKD alone (without copathologies)? Does it mean that GLP-1RAs are not beneficial in people without T2D or obesity?
Excellent questions, which is why I’m staying away from GLP-1 meds for now, as there’s not enough data in low-normal weight non-diabetics. Interesting drugs, need more studies - I’m especially interested in the neuroprotective potential.
I’m not diabetic but have seen improvements in my labs without changing other variables with Retatrutide so I’m a believer
2 Likes
I’m also optimistic but I wonder: if they’re so good how come ZERO companies are exploring them in non diabetic / non overweight? (except one AD trial) CKD and HF are diseases of aging and massive markets.
1 Like
I think it’s coming soon
1 Like
The money is probably not there. That’s is, there is money to be made, but it pales in comparison to what’s in the obesity/diabetes market.
1 Like
It’s not. Look at the pipeline: Experience with GLP-1s - #472 by adssx
They already got approval in those markets. They could make more money by adding indications. And they’re doing it. Read the pipeline: they WANT to expand to CKD and HF but… only as copathologies in people with T2D and/or obesity! How come they decided to EXCLUDE non-diabetics / non-obese from their CKD and HF trials? Surely they must think that these drugs won’t be beneficial in those populations. Otherwise why? The trials are already paid. It costs the same to do a trial on n=1000 people with (CKD + obesity) vs (CKD with or without obesity).
1 Like
The effect might not be large enough in people with non-diabetic CKD.
The problem could be the added complexity of giving a drug that causes profound weight loss to a normal weight person.
Compared to those of us who are motivated to optimize health with exercise and nutrition, the typical non-obese trial participant could run into a lot of trouble on an incretin mimetic.
1 Like
And that’s exactly why I think they might not have benefits in non T2D / obesity.
They could give them a lower dose. Less than 5% weight loss. They could limit the trials with people who are not underweight. Or BMI > 20 kg/m² (instead of 24.9).
Additionally, not all GLP-1RAs cause a lot of weight loss. Most first generations GLP1-RAs don’t cause much weight loss (exenatide, albiglutide, etc.).
1 Like
Sure, but they also require once daily injections. Even with positive results, how marketable would they be? If anything, maybe Eli Lilly will eventually do some trials with low dose orforglipron in non-obese non-diabetics (if they can find enough subjects in the USA 
)
No. Exenatide, albiglutide, dulaglutide, and liraglutide are once-weekly.
2 Likes
Ok, good points. Perhaps smaller doses and weaker potency at the GLP-1 receptor might also mean less potent pleiotropic effects, even if such effects are proven to be independent of fat loss.
I don’t know what the IP situation is when it comes to adding indications.